RevolutionLogo.png
Revolution Medicines to Participate in Upcoming Investor Conferences
November 09, 2022 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 16:05 ET | Cyclacel
- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - - Two Partial Responses in Lymphoma and...
RevolutionLogo.png
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
November 07, 2022 16:05 ET | Revolution Medicines, Inc.
Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to...
RevolutionLogo.png
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
November 01, 2022 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Hookipa Pharma Logo Square.png
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
October 20, 2022 07:00 ET | HOOKIPA Pharma Inc.
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
RevolutionLogo.png
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
September 22, 2022 07:00 ET | Revolution Medicines, Inc.
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to...
RevolutionLogo.png
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
September 01, 2022 16:05 ET | Revolution Medicines, Inc.
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE...
RevolutionLogo.png
Revolution Medicines to Participate in Upcoming Investor Conferences
August 31, 2022 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
August 09, 2022 16:02 ET | Revolution Medicines, Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...
RevolutionLogo.png
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
July 28, 2022 16:02 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...